专题:Urticaria and Related Conditions

This cluster of papers focuses on the diagnosis, classification, and management of urticaria, particularly chronic spontaneous urticaria. It explores the role of autoimmune factors, the effectiveness of treatments like omalizumab, and the impact on quality of life. Additionally, it delves into the association with thyroid autoimmunity and the use of autoantibodies as markers for diagnosis.
最新文献
Insights into Pathogenesis of Chronic Spontaneous Urticaria

article Full Text OpenAlex

Safety of Remibrutinib in Chronic Spontaneous Urticaria: A Pooled Analysis of REMIX-1 and REMIX-2 Trials

review Full Text OpenAlex

Endotypes in chronic spontaneous urticaria

article Full Text OpenAlex

Targeting immune dysregulation in chronic spontaneous urticaria: beyond antihistamines

review Full Text OpenAlex

Clinical Evolution of Acute Urticaria and Association With IgE Autoantibodies

article Full Text OpenAlex

The Overall Burden of Chronic Spontaneous Urticaria – The Current Landscape

article Full Text OpenAlex

Neuro-immune interactions in urticaria:a pruritus-centric dissection

review Full Text OpenAlex

Integrated Transcriptomic Analysis Unveils Hub Genes and Immune Dysregulation in Chronic Spontaneous Urticaria Pathogenesis

article Full Text OpenAlex

Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria

article Full Text OpenAlex

Dupilumab in Patients With Chronic Spontaneous Urticaria

article Full Text OpenAlex

近5年高被引文献
Urticaria

review Full Text OpenAlex 387 FWCI11.9267

Autoimmune chronic spontaneous urticaria

review Full Text OpenAlex 307 FWCI8.5659

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

article Full Text OpenAlex 197 FWCI44.3733

Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

article Full Text OpenAlex 171 FWCI46.1864

Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances

review Full Text OpenAlex 171 FWCI5.1641

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria

article Full Text OpenAlex 165 FWCI20.0066

Chronic Spontaneous Urticaria

review Full Text OpenAlex 153 FWCI11.6002

Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria

article Full Text OpenAlex 138 FWCI15.4219

Remibrutinib in Chronic Spontaneous Urticaria

article Full Text OpenAlex 126 FWCI76.6058

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

review Full Text OpenAlex 114 FWCI8.6433